tucidinostat + cyclophosphamide + doxorubicin + vincristine + prednisone

A multi-agent chemotherapy regimen combining **tucidinostat**, a selective oral histone deacetylase (HDAC) inhibitor, with **cyclophosphamide** (an alkylating agent), **doxorubicin** (an anthracycline DNA intercalator and topoisomerase II inhibitor), **vincristine** (a vinca alkaloid mitotic inhibitor), and **prednisone** (a synthetic glucocorticoid). This regimen, an experimental variant of the standard CHOP protocol, is under study primarily for the treatment of newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL) and other aggressive lymphomas, leveraging tucidinostat's epigenetic modulation to potentially enhance chemotherapy efficacy and overcome resistance. Tucidinostat acts by inhibiting class I and IIb HDACs, leading to altered gene expression and tumor cell apoptosis. The combination has demonstrated synergistic and additive effects in clinical studies, with evidence for improved response rates and progression-free survival compared to CHOP alone.

Other names

tucidinostat + CHOP